RITALINE L.P. 10 mg, gélule à libération prolongée
DR240305
Approved small_molecule active
Quick answer
RITALINE L.P. 10 mg, gélule à libération prolongée for Attention Deficit Disorder with or without Hyperactivity (ADHD) is a neurodevelopmental disorder characterized by disabling symptoms of inattention and/or hyperactivity-impulsivity beginning before the age of 12 with significant personal, social, academic and/or occupational impact (American Psychiatric Association 2013). This disorder, whose prevalence is around 5% in children and adolescents, affects 2.6% of adults (American Psychiatric Association 2013; Song et al. 2021). is a Approved program (small_molecule) at Tour Hekla with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Tour Hekla
- Indication
- Attention Deficit Disorder with or without Hyperactivity (ADHD) is a neurodevelopmental disorder characterized by disabling symptoms of inattention and/or hyperactivity-impulsivity beginning before the age of 12 with significant personal, social, academic and/or occupational impact (American Psychiatric Association 2013). This disorder, whose prevalence is around 5% in children and adolescents, affects 2.6% of adults (American Psychiatric Association 2013; Song et al. 2021).
- Phase
- Approved
- Modality
- small_molecule
- Status
- active